Investigating a protein linked to blood clotting and pregnancy complications
Official title: Structural Studies of Beta-2 glycoprotein I in the Antiphospholipid Syndrome
Funded at Saint Louis University · NIH-10762475 · Data updated 2026-11-12
This study is looking at a protein called beta-2 glycoprotein I to learn more about how it affects people with Antiphospholipid Syndrome, which can cause serious blood clots and pregnancy issues, so we can find better ways to diagnose and treat this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | December 15, 2019 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $380,866 |
| NIH project number | 5R01HL150146-05 |
| Project ID | NIH-10762475 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Antiphospholipid Syndrome or those experiencing recurrent pregnancy complications related to blood clotting.
✕Less likely to help
Patients without a diagnosis of Antiphospholipid Syndrome or those not experiencing related complications may not benefit from this research.
What this research studies
This research focuses on Beta-2 glycoprotein I (b2GPI), a protein that plays a crucial role in the autoimmune disorder Antiphospholipid Syndrome (APS). Patients with APS often experience dangerous blood clots and complications during pregnancy. The study aims to better understand the different types of anti-b2GPI antibodies and their effects, which could lead to improved diagnostic tests and treatment options. By analyzing the structure of b2GPI, researchers hope to identify patients at higher risk for thrombosis and develop more effective therapies.
Why it matters
Potential benefit: If successful, this research could lead to better diagnosis and treatment options for patients with Antiphospholipid Syndrome, potentially reducing the risk of blood clots and pregnancy complications.
How similar studies have gone: Previous research has shown promise in understanding the role of b2GPI in APS, but this specific approach to studying its structure and implications is relatively novel.
Where this research is happening
-
Saint Louis University
Saint Louis, United States Active
Researchers
- Principal investigator: Pozzi, Nicola — Saint Louis University
- Study coordinator: Pozzi, Nicola
Related research
Other NIH-funded projects on the same topics.
-
How immune cells clear damaged mitochondria in antiphospholipid syndrome
This project is seeing if fixing a cell-cleanup process in white blood cells can reduce harmful blood clots in adults with antiphospholipid syndrome.
-
Decoding neutrophil membranes in antiphospholipid syndrome
A patient-facing look at a study that aims to understand how neutrophils and cell membranes contribute to blood clots in antiphospholipid syndrome and how this could lead to new ways to diagnose and treat the condition.
-
Thrombocytopenia Trajectories in antiphospholipid syndrome
This study tests whether patterns in platelet counts over time can predict outcomes for adults with antiphospholipid syndrome.
-
BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases
This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.
-
Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies
Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.
-
YTS109 cell therapy for relapsed or treatment‑resistant autoimmune diseases
This will try a single infusion of YTS109 immune cells in adults 18–65 with relapsed or treatment‑resistant autoimmune diseases such as lupus, Sjogren’s, systemic sclerosis, inflammatory myopathies, or ANCA‑associated vasculitis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.